© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 5, 370-372,
March 1, 2000
© 2000 Oxford University Press
NEWS |
Clinical Trials: Finding Balance In Randomization
Years ago a prominent cancer researcher asked the provocative question, "Is there any mileage left in the randomized clinical trial?"
Emil J. Freireich, M.D., a leukemia expert at the University of Texas M. D. Anderson Cancer Center in Houston, rejected the conventional view of the randomized trial as the gold standard in clinical research. He compared it instead to an old Tin Lizzy, a car that served long and well but is now fit only for museum or junkyard. Answering his own question in the negative, he laid out ethical objections to randomized trials and asserted that many clinical scientists have abandoned such trials as the best way to gather medical knowledge.
|
Years later, though, that claim appears overstatedor at least premature. The randomized, controlled trial reigns today as firmly as ever, and researchers have been slow to embrace alternatives or even to modify the
Equipoise
Justifiably Participate
Eliminating Diversity
Logical Inconsistency
Practicing Informed Consent
Ethical Tensions
